Literature DB >> 3717938

Aztreonam treatment of gram-negative septicemia.

D Pierard, J Boelaert, H W Van Landuyt, A Naessens, L Huyghens, S Lauwers.   

Abstract

Seventy-five aztreonam treatment courses in 74 patients with gram-negative septicemia resulted in 56 clinical cures (75%), 12 partial clinical cures (16%), and 7 clinical failures (9%). Eradication of the original pathogen from the blood was obtained in all patients but two, who had relapses 1 and 4 days, respectively, after treatment. In nine patients (12%) a superinfection was reported. Significant adverse reactions were limited to one transient urticarial rash. Aztreonam may prove to be an effective alternative for the treatment of gram-negative septicemia, but superinfections should be carefully monitored.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3717938      PMCID: PMC176412          DOI: 10.1128/AAC.29.2.359

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  In vitro activity and beta-lactamase stability of a monobactam, SQ 26,917, compared with those of aztreonam and other agents.

Authors:  H C Neu; P Labthavikul
Journal:  Antimicrob Agents Chemother       Date:  1983-08       Impact factor: 5.191

2.  SQ 26,776: in-vitro antibacterial activity and susceptibility to beta-lactamases.

Authors:  I Phillips; A King; K Shannon; C Warren
Journal:  J Antimicrob Chemother       Date:  1981-12       Impact factor: 5.790

3.  In-vitro activity of monobactam, SQ 26,776, against Gram-negative bacteria.

Authors:  A Percival; E Thomas; C A Hart; P Karayiannis
Journal:  J Antimicrob Chemother       Date:  1981-12       Impact factor: 5.790

4.  SQ 26,776, a novel beta-lactam: an in-vitro comparison with other antimicrobial agents.

Authors:  R Wise; J M Andrews; J Hancox
Journal:  J Antimicrob Chemother       Date:  1981-12       Impact factor: 5.790

5.  Monocyclic beta-lactam antibiotics produced by bacteria.

Authors:  R B Sykes; C M Cimarusti; D P Bonner; K Bush; D M Floyd; N H Georgopapadakou; W M Koster; W C Liu; W L Parker; P A Principe; M L Rathnum; W A Slusarchyk; W H Trejo; J S Wells
Journal:  Nature       Date:  1981-06-11       Impact factor: 49.962

6.  Serum bactericidal activity of aztreonam, cefoperazone, and amikacin, alone or in combination, against Escherichia coli, Klebsiella pneumoniae, Serratia marcescens, and Pseudomonas aeruginosa.

Authors:  Y Van Laethem; M Husson; J Klastersky
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

7.  Azthreonam (SQ 26,776), a synthetic monobactam specifically active against aerobic gram-negative bacteria.

Authors:  R B Sykes; D P Bonner; K Bush; N H Georgopapadakou
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191

8.  Evaluation of aztreonam in the treatment of severe bacterial infections.

Authors:  J Romero-Vivas; M Rodríguez-Créixems; E Bouza; T Hellín; A Guerrero; J Martínez-Beltrán; M García de la Torre
Journal:  Antimicrob Agents Chemother       Date:  1985-08       Impact factor: 5.191

9.  Treatment of serious gram-negative infections with aztreonam.

Authors:  R N Greenberg; P M Reilly; K L Luppen; R McMillian; M Bollinger; S M Wolk; T B Darji; A A Noorani
Journal:  J Infect Dis       Date:  1984-11       Impact factor: 5.226

10.  Enterococcal superinfection and colonization with aztreonam therapy.

Authors:  P H Chandrasekar; B R Smith; J L LeFrock; B Carr
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.